- Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive.
- Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations.
- Includes a timely section on innovative future therapies.
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
Key Features
- Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive.
- Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations.
- Includes a timely section on innovative future therapies.
| ISBN | 9780323581226 |
|---|---|
| Product Format | Book |
| Publication Date | 2018 |
| Author Information | By Sara Hurvitz, MD and Kelly McCann |
| Table of Content | Background/testing 1. The HER2 alteration in breast cancer 2. HER2 testing in the era of changing guidelines Advanced Disease 3. Optimal first-line treatment of HER2+ advanced disease 4. Second line therapy and beyond 5. HER2+ CNS metastases Therapeutics 6. Neoadjuvant therapy 7. Adjuvant therapy 8. Outcomes based on HR status in early stage disease 9. De-escalation of therapy for small tumor Toxicity considerations 10. Cardiac toxicity of HER2-targeted regimens 11. Non-cardiac toxicity of HER2-targeted therapy Therapies on the horizon 12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc) 13. Harnessing the immune system in HER2+ disease 14. Biosimilars |
| Publication Date | 16-08-2018 |
| Pages | 250 |
| Trim | 235 x 191 (7 1/2 x 9 1/4) |
| Stock Status | In Stock |
| deltacomm1code | Books |
